Grade 4 adverse events were seen in one ( 2 % ) of 54 patients in each of groups 1 and 3 and in three ( 10 % ) of 31 patients in group 2 , whereas grade 3-4 events were reported in less than 5 % of all patients , except increased blood amylase concentration .